Prospective, randomised (using minimisation), double-blind, placebo controlled study to evaluate the safety and efficacy of human normal immunoglobulin as a prophylactic agent against infections in patients with high grade gliomas

Start Date28 Jul 2008

Sponsor / Collaborator-

100 Clinical Results associated with Immuglo

100 Translational Medicine associated with Immuglo

100 Patents (Medical) associated with Immuglo

Literatures (Medical) associated with Immuglo

26 Oct 2021·World Journal of Clinical Cases

Diagnosis and treatment of acute graft-versus-host disease after liver transplantation: Report of six cases

Author: Hu, Liang-Shuo ; Liu, Chang ; Tian, Min ; Zhang, Xiao-Gang ; Guo, Kun ; Wang, Bo ; Li, Yu ; Liu, Xue-Min ; Yu, Liang ; Shi, Jian-Hua ; Lyu, Yi

BACKGROUNDGraft-versus-host disease (GVHD) following liver transplantation (LT) is an unpredictable complication with poor outcome. However, consensus regarding the diagnosis and therapeutic regimen for the disease is yet lacking. The present study summarized the clinical experience on the diagnosis and treatment of acute GVHD (aGVHD) following LT and reviewed the pertinent literature.CASE SUMMARYBetween January 1^st, 2000 and December 31^st, 2020, a total of 1053 LT were performed in the First Affiliated Hospital of Xi'an Jiaotong University. Six recipients developed aGVHD with clinical symptoms of fever, rash, diarrhea, and pancytopenia. The incidence of aGVHD was 0.57%. The median time from LT to the clinical presentation of aGVHD was 22.17 d. The median time from the beginning of the clinical symptom to histopathological diagnosis was 7.5 d. All six cases underwent treatment of immunosuppressant adjustment, corticosteroids, human normal immunoglobulin, and antithymocyte globulin/IL-2 antagonists. Despite intensive treatment strategies, 4 patients were deceased due to sepsis, multiple organ failure, and cerebral hemorrhage. The remaining two cases were discharged as treatment successfully. However, one died because of tuberculosis infection on the 6th month of follow-up, the other one was alive healthy during 30 mo of follow-up.CONCLUSIONThe rapid diagnosis of aGVHD is mainly based on the time from the first symptom, histopathological features, and the donor T-lymphocyte chimerism. Our cases report highlights massive corticosteroid therapy and age difference between donors and recipients could accelerate to aGVHD. Moreover, gut microbial interventions and donor-targeted serotherapy may provide novel therapeutics.

03 Mar 1995·Communicable disease report. CDR review

A collaborative case control study of sporadic hepatitis A in England.

Review

Author: Maguire, H C ; O'Mahony, M ; Perry, K R ; Handford, S ; Begg, N T ; Waight, P ; Nicholas, S ; Parry, J V

A case control study of sporadic hepatitis A was carried out in 201 districts in England from July 1990 to June 1991. The aims were to determine the risk factors associated with the infection and to identify individuals or groups who might benefit from prophylactic measures, such as human normal immunoglobulin or hepatitis A vaccine. Factors associated with risk of hepatitis A included travel abroad (odds ratio (OR) 19.8; 95% confidence interval (CI) 4.87-80.6), a household contact with hepatitis A (OR 13.5; 95% CI 6.49-28.0) and sharing a household with a child aged 3 to 10 years (OR 1.57; 95% CI 1.1-2.22). This study provided no clear evidence of increased risk in health care workers, teachers, or other occupational groups. A non-significant trend towards an increased risk in nursery nurses and child minders aged 20 to 29 years was observed. Pre-exposure prophylaxis with hepatitis A vaccine may be considered for people who travel frequently to areas where hepatitis A is highly or moderately endemic. Post-exposure prophylaxis with human normal immunoglobulin should be given to contacts of known cases in accordance with national guidelines. Immunoglobulin alone has been recommended in outbreaks, but the use of vaccine alone or combined with immunoglobulin should be evaluated.

20 Jan 1995·Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke

[Hepatitis A in Oslo].

Article

Author: Espinoza, R ; Hasle, G

During the last six years we have registered 237 persons with acute hepatitis A in Oslo, 96 of them with non-Scandinavian names. The number with non-Scandinavian names is increasing. Almost all the hepatitis A patients with non-Scandinavian names are children, and two of three had been infected in Pakistan. Adult immigrants from countries where hepatitis A is endemic do not need any prophylaxis against hepatitis A. 29,800 travellers were given human normal immunoglobulin at our department during the last five years and none of them acquired hepatitis A. To prevent import of hepatitis A it is of particular importance to give human normal immunoglobulin or hepatitis A vaccine to all children of immigrants before they visit their parents' country.

100 Deals associated with Immuglo

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Wiskott-Aldrich Syndrome	IN	Hemarus Therapeutics Ltd.	25 Aug 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Immuglo

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation